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The efficacy and safety of topiramate in patients with intractable mixed seizures, mental retardation (MR), and developmental
disabilities (DD) were investigated. Twenty patients (eight females and 12 males) aged 21–57 years old with intractable epilepsy
with mixed seizures, MR [profound (five), severe (three), moderate (two), mild (eight) and borderline (two)], and DD were
treated with adjunctive topiramate 25 mg per day for 1 week followed by titration to clinical response (range 50–350 mg per
day). Other antiepileptic drugs (AEDs) were decreased simultaneously. Topiramate therapy was discontinued in four patients
for adverse events consisting of disorientation, unsteadiness, and pneumonia (one patient); anaphylactic shock from a tuna
fish allergy (one); patient choice (one); and loss to follow-up (one). Seizures improved by >50% in 11 of 16 patients (69%).
Two patients (13%) were seizure free, including one patient who prior to topiramate therapy was seizure free but experiencing
an intolerable adverse effect during therapy with another AED. Seizure duration and/or severity decreased in seven patients
(44%). An increase in alertness was observed in 11 patients (59%). Topiramate was associated with improvement in seizure
severity and alertness in this series and may be useful as adjunctive therapy in patients with mixed seizures, MR, and DD.
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INTRODUCTION
Epilepsy is a co-existing neurological disorder in 40–
50% of individuals with mental retardation (MR)
and developmental disabilities (DD). Many of these
patients have seizures that are not controlled satis-
factorily with their current antiepileptic drug (AED)
therapy. For example, in a chart review of 100 patients
with MR, DD, and intractable seizures, we found
that 40% of patients were still experiencing seizures
despite treatment with two to three AEDs1. Thus,
a substantial number of patients with MR and
DD could benefit from improved seizure con-
trol.
Topiramate has been shown to be effective as
adjunctive therapy in a wide range of seizure types,
including partial-onset seizures2–7, seizures associ-
ated with Lennox–Gastaut syndrome8, and primary
generalized tonic–clonic seizures9. Most commonly
reported side effects in the double-blind adjunctive
therapy trials in adults with refractory partial onset
seizures were related to the central nervous system and
included somnolence, dizziness, abnormal thinking,
fatigue, ataxia, confusion, paresthesia and impaired
concentration10. Most adverse events with topiramate
tended to appear early in the course of treatment and
to resolve with continuing therapy. Cognitive and CNS
adverse effects may occur less frequently with a lower
initial dose of topiramate and slower titration11.
It is uncertain whether patients with underlying
static CNS dysfunction may be more, or less suscep-
tible to potential CNS-related side effects of AEDs,
or whether cognitive function will improve as a result
of improved seizure control, or a reduction of total
AED requirements. This evaluation was undertaken to
determine the usefulness of topiramate in individuals
with intractable mixed seizures, MR, and DD.
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METHOD
Patients
Study patients were selected based on a chart review of
368 epilepsy patients who were >21 years of age, had
MR and DD, and were being treated at the neurology
clinic of the Westchester Institute for Human Develop-
ment. Severity of mental retardation was determined
through a combination of IQ scores and psychological
evaluation and was graded as profound, severe,
moderate, mild, or borderline. Eligible patients had
the following entry criteria: mixed seizures (i.e. mixed
generalized seizures or mixed partial and generalized
seizures) that were uncontrolled by treatment with
standard or newer AEDs; or intolerable adverse
effects with current AED therapy. Seizure episodes
were classified according to guidelines for seizure
classification of the International League Against
Epilepsy12. Patients with a history of renal stones
were excluded. The study protocol was approved by
the institutional review board, and written informed
consent was obtained from patients or their guardians
prior to study entry.
Procedure
Topiramate therapy initially was given in addition to
baseline AEDs at a dosage of 25 mg per day for
1 week. The topiramate dosage was then increased
to a level that was dependent on seizure frequency
and tolerability. Concomitant baseline AEDs were
gradually withdrawn when appropriate. Based on
data forms completed by patients and/or care givers,
the following were monitored during topiramate
therapy: seizure occurrence (time, type, and duration
of seizures); adherence to AED therapy; adverse
events; precipitants of seizures; and the number of
emergency room visits and the treatment provided in
the emergency room. At the final study visit, inves-
tigator’s and patients’ global evaluations of overall
improvement were recorded. The investigator rated
improvement as worse, none, minimal, moderate, or
marked; and patients assessed their improvement as
poor, fair, good, or excellent. Based on physician’s
evaluations during clinic visits and information from
care givers, adverse events were determined. During
study visits, patients and/or care givers were asked
specifically about patient alertness. Clinical laboratory
tests (i.e. AED plasma levels, CBC, and serum
electrolytes) were performed during the first 2–
4 weeks of topiramate therapy and then every 3 months
thereafter.
RESULTS
Twenty patients (eight females and 12 males) entered
the study and were treated with topiramate. Demo-
graphic characteristics of these patients are presented
in Table 1. The age of the patients ranged from 21–
57 years old. The level of mental retardation was:
profound in five patients, severe in three, moderate in
two, mild in eight, and borderline in two. The seizures
experienced by these patients were uncontrolled on
various combinations of phenytoin, carbamazepine,
phenobarbital, primidone, lamotrigine, or divalproate
sodium.
Table 1: Patient characteristics.
Variable
N 20
Age 21–57 years
Gender
Female 8
Male 12
Baseline seizure frequency
Median 4.5/month
Range 0–20/month
Seizure type, N (%)
Generalized tonic–clonic 19 (95%)
Partial complex 16 (80%)
Atonic 8 (40%)
Tonic 7 (35%)
Clonic 6 (30%)
Myoclonic 3 (15%)
Drop attacks 2 (10%)
Absence 1 (5%)
Mental retardation, N (%)
Profound 5 (25%)
Severe 3 (15%)
Moderate 2 (10%)
Mild 8 (40%)
Borderline 2 (10%)
Baseline AEDs
1 AED 5%
2 AEDs 55%
3 AEDs 40%
Four patients discontinued topiramate treatment
during the study for reasons presented in Table 2.
Among the 16 patients completing the trial, the mean
dosage of topiramate was 189 mg per day (range 50–
350 mg per day) and the mean duration of therapy
was 42 weeks (range 20–54 weeks). Seizure frequency
was reduced by >50% in 11 of 16 patients (69%)
and two patients were seizure free (13%) (Fig. 1).
There was no change in seizure frequency in three
patients, including one patient who was seizure-free at
baseline (but experiencing intolerable adverse effects
while on other AED therapy) and remained seizure-
free during topiramate therapy, and seizures increased
in two patients. Seizure duration and/or severity was
reduced in seven patients (44%). Global evaluations
of improvement were obtained in 18 patients. Based
on investigator global evaluations, improvement was
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marked to moderate in 15 patients and none to minimal
in three patients. Overall improvement was rated as
excellent by 13 patients, fair to good by one patient
and poor to fair or fair by four patients.
Table 2: Treatment discontinuations.
Reason N
Adverse events (disorientation, unsteadiness, pneumonia) 1
Anaphylactic shock (allergy to tuna fish) 1
Patient choice 1
Lost to follow-up 1
The concomitant AEDs before and after topiramate
therapy are listed in Table 3 for the 16 patients who
completed the study. In 11 patients (69%) at least
one baseline AED was discontinued. Reductions in
baseline AED dosages were achieved in 13 patients.
Improved alertness was evidenced in 11 of 16 patients
(69%). The emergency room visits for seizures did
not increase or decrease. Adverse events noted during
the study are presented in Table 4. None of the
adverse events were serious although one patient
discontinued topiramate (see Table 2 for treatment
discontinuations).
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Fig. 1: Percentages of patients achieving a >50% reduction
from baseline in the average monthly rate of seizures or
seizure freedom.
Table 3: Concomitant antiepileptic drugs in the 16 patients
completing the study.
Number of patients
Before topiramate After topiramate
Valproate 9 7
Phenytoin 6 6
Carbamazepine 8 5
Lamotrigine 5 2
Gabapentin 4 0
Phenobarbital/primidone 4 3
Table 4: Adverse events.
Adverse event N
Behavior problem 3
Decreased alertness 3
Drowsiness 1
Increase in seizures 1
Abnormal movements (due to valproate) 1
Disorientation, unsteadiness, pneumonia
Low platelets 1
Low WBC 1
DISCUSSION
In the present study, topiramate as adjunctive therapy
resulted in clinically significant improvement in
seizure control (a reduced seizure frequency of>50%)
in 69% of adults with MR, DD, and intractable mixed
seizures that were not satisfactorily controlled with
other AEDs. Two patients (13%) were seizure free,
including one patient who was seizure free before
admission to this study but experienced an intolerable
adverse effect while on previous AED treatment.
In addition, the duration and/or severity of seizures
was reduced in 44% of patients. In comparison, five
multicenter placebo-controlled trials of topiramate
as adjunctive therapy for partial-onset seizures in
adults demonstrated >50% reductions from baseline
in partial-onset seizure rates in 41% (146/360) of
patients treated with topiramate compared to 10%
(17/174) of placebo-treated patients2–7. Four percent
of topiramate-treated patients became seizure free
while no patients treated with placebo became seizure
free. Similarly, in a multicenter placebo-controlled
study in adults and children with generalized tonic–
clonic seizures, the seizure rates decreased from base-
line by>50% in 56% (22/39) of the topiramate group
and in 20% (8/40) of the placebo group and 13%
(5/39) of topiramate-treated patients became seizure
free vs. 5% (2/40) of placebo-treated patients8.
In this study, a high level of seizure control was
obtained with minimal incidence of adverse events.
Although topiramate has been associated with CNS
side effects, topiramate at doses of 50–350 mg
per day was well tolerated in this trial with few
discontinuations due to adverse events. Topiramate
appears to be both safe and effective as an add-on
therapy in patients with MR and DD, who have not
achieved satisfactory control of their mixed seizures
with other currently marketed AEDs.
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EDITOR’S NOTE
The use of the term mental retardation is not current
practice in UK writings, but is perfectly acceptable in
the USA, so I have kept the term in this paper, and not
altered it.
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